{
    "clinical_study": {
        "@rank": "88852", 
        "arm_group": [
            {
                "arm_group_label": "Investigational (ESS505) / Control Device (ESS305)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Investigational (ESS505-A)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study has been designed to evaluate an investigational model of the Essure System for\n      Permanent Birth Control. The investigational device is designed to offer all the advantages\n      of the currently approved device. In addition, the investigational device offers immediate,\n      permanent contraception without a three-month waiting period or 90-day confirmation test.\n      This study has been designed to evaluate the effectiveness of the investigational device in\n      causing tubal occlusion from insert placement through three months of wearing."
        }, 
        "brief_title": "ESS505 Pre-hysterectomy Protocol", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Contraception", 
        "detailed_description": {
            "textblock": "This study has previously been posted by Conceptus, Inc. (US).\n\n      After acquiring Conceptus, Inc., Bayer HealthCare AG (Germany) is the sponsor of the trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who are scheduled to undergo a Laparoscopically Assisted Vaginal\n             Hysterectomy (LAVH), Total Abdominal Hysterectomy (TAH), Total Vaginal Hysterectomy\n             (TVH), Total Laparoscopic Hysterectomy (TLH) with Bilateral Total Salpingectomy or\n             Bilateral Salpingo-oophorectomy (BSO), or Laparoscopic Supracervical Hysterectomy\n             (LSH)\n\n          -  Subjects who are 18 years of age and older\n\n          -  Subjects who are able and willing to provide written informed consent\n\n          -  Subjects who agree to use a contraceptive method following Essure placement until the\n             hysterectomy procedure\n\n        Exclusion Criteria:\n\n          -  Subjects with bilateral proximal tubal occlusion\n\n          -  Subjects who have undergone fallopian tube sterilization\n\n          -  Subjects with known endometrial or myometrial pathology which is likely to prevent\n             access to the fallopian tube ostia\n\n          -  Subjects who are post-menopausal\n\n          -  Subjects with pelvic inflammatory disease (PID)\n\n          -  Subjects with gynecologic malignancy\n\n          -  Pregnancy or suspected pregnancy\n\n          -  Delivery or termination of a pregnancy less than 6 weeks before Essure micro-insert\n             placement\n\n          -  Known allergy to contrast media\n\n          -  Any general health condition that may represent, in the opinion of the Investigator,\n             an increased potential risk associated with participation"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664052", 
            "org_study_id": "17035", 
            "secondary_id": "ESS505-002"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Investigational (ESS505) / Control Device (ESS305)", 
                    "Investigational (ESS505-A)"
                ], 
                "intervention_name": "ESS505 (BAY1454033)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Investigational (ESS505) / Control Device (ESS305)", 
                "intervention_name": "ESS305 (Essure, BAY1454032)", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Investigational (ESS505-A)", 
                "intervention_name": "ESS505-A (Essure, BAY1454033)", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Regina", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S4P 0W5"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chihuahua", 
                        "country": "Mexico", 
                        "zip": "31350"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Mexico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "ESS505 Pre-hysterectomy Protocol: Safety and Short Term Effectiveness Study", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Mexico: Federal Commission for Sanitary Risks Protection"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Ability of the insert to occlude the fallopian tube", 
            "safety_issue": "No", 
            "time_frame": "0-3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}